Floatz logo

Yttrium Y 90 Basiliximab

Recurrent Hodgkin Lymphoma

City of Hope Medical Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

149 Active assets in the Recurrent Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Yttrium Y 90 Basiliximab is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
mature T-cell and NK-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →